Your session is about to expire
← Back to Search
Neuromodulation Device
RENOVA iStim™ System for Overactive Bladder (OASIS Trial)
N/A
Recruiting
Led By John Heesakkers, MD
Research Sponsored by BlueWind Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Female aged 18 or greater (21 in the US)
Female aged 18 or greater (21 in the US)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
OASIS Trial Summary
This trial is testing a new implantable device to treat overactive bladder. The device is placed near the tibia and sends electrical signals to the nerves that control the bladder. The study will evaluate the safety and efficacy of the device.
Who is the study for?
This trial is for mentally competent women aged 18+ (21+ in the US) who have been diagnosed with overactive bladder (OAB) for at least 6 months. It's not suitable for those with significant medical conditions that could affect the study, breastfeeding women, patients with mainly stress incontinence, a life expectancy under one year, or those diagnosed with interstitial cystitis/bladder pain syndrome.Check my eligibility
What is being tested?
The OASIS study is testing the BlueWind RENOVA iStim™ System's safety and effectiveness. This system is an implantable device designed to treat overactive bladder by stimulating nerves in the tibia.See study design
What are the potential side effects?
While specific side effects are not listed here, similar neuromodulation treatments can cause discomfort at the implant site, movement issues of the stimulated limb, changes in bowel movements or urinary patterns.
OASIS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a woman aged 18 or older (21 or older in the US).
Select...
I am a woman aged 18 or older (21 or older in the US).
Select...
I understand and can follow the study's requirements.
Select...
I have been diagnosed with urge urinary incontinence for 6 months or more.
Select...
I understand and can follow the study's requirements.
Select...
I have been diagnosed with urinary urgency incontinence for at least 6 months.
OASIS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Improvement in urinary urgency incontinence (UUI) episodes based on patient voiding diary
Safety - incidence of adverse events
OASIS Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment armExperimental Treatment1 Intervention
RENOVA iStim™ System implanted patients
Find a Location
Who is running the clinical trial?
BlueWind MedicalLead Sponsor
9 Previous Clinical Trials
482 Total Patients Enrolled
John Heesakkers, MDPrincipal InvestigatorMaastricht University Medical Centre
3 Previous Clinical Trials
1,110 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am a woman aged 18 or older (21 or older in the US).I am a woman aged 18 or older (21 or older in the US).Mainly experiencing stress incontinence.The doctors think you may have less than a year to live.I have been diagnosed with interstitial cystitis or bladder pain syndrome.I understand and can follow the study's requirements.I have been diagnosed with urge urinary incontinence for 6 months or more.I understand and can follow the study's requirements.I have been diagnosed with urinary urgency incontinence for at least 6 months.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment arm
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Overactive Bladder Patient Testimony for trial: Trial Name: NCT03596671 — N/A
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
Maryland
What site did they apply to?
University of California Irvine
Chesapeake Urology - Owing Mills
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0
Why did patients apply to this trial?
I think this is important research sinc I know someone who had this problem.
PatientReceived 2+ prior treatments
Recent research and studies
Share this study with friends
Copy Link
Messenger